CSL Ltd (ASX: CSL) shares were sold off in 2025. Let's find out why and see if this is a buying opportunity for ...
Approaching the final week of November CSL Ltd ADR (OTCMKTS: CSLLY) received some good news as the United States Food and Drug Administration approved CSL Behring’s new gene therapy drug, HEMEGENIX ...
Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...
As investors, we’re irresistibly drawn to milestones, and the past year has provided a jackpot of them. The ASX stormed past 8,000, Bitcoin soared beyond US$100,000, NVIDIA hit a mind-boggling US$3 ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and ...
MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global ...
One of the hardest questions for investors is whether a falling share price signals a buying opportunity or a warning to stay away. The old saying warns against "catching a falling knife." This means ...
CSL Limited achieved a +3% earnings beat for 1H FY 2024, and the company's full-year FY 2024 financial guidance was left unchanged. But CSL Limited's CSL112 trial results were unfavorable, which ...
CSL Limited has left its current fiscal year financial guidance unchanged, which I deem to be too conservative. There are various indicators suggesting that the company's actual topline expansion and ...
Shares of the Australia-based CSL Ltd. (AU:CSL) fell by over 4% as of writing despite the company achieving higher profit in FY24. The company reported an NPAT (net profit after tax) attributable to ...